Burke William Acquires Shares in Axogen, Inc. (AXGN)

On June 19, 2026, Burke William purchased 14,150 shares of Axogen, Inc. (NasdaqCM: AXGN). The transaction wasn't part of a pre-planned trading program, signaling a potential vote of confidence in the company's future.

Other Institutional Activity in Axogen, Inc.

Several institutional investors have also adjusted their positions in Axogen, Inc. First Light Asset Management, LLC reduced its holdings by 1,230,558 shares, finishing with 4,002,768 shares valued at approximately $132.6 million, marking a 23.5% decrease. Meanwhile, BlackRock, Inc. increased its stake by 151,414 shares, now holding 3,870,851 shares worth about $128.2 million, reflecting a 4.1% increase. Morgan Stanley significantly boosted its position by 536,112 shares, ending with 3,122,982 shares valued at $103.5 million, a 20.7% increase. Vanguard Capital Management LLC opened a new position with 2,291,563 shares valued at approximately $75.9 million. Arrowmark Colorado Holdings LLC also increased its holdings by 441,157 shares to 1,915,439 shares, valued at $63.5 million, a 29.9% increase.

Axogen, Inc. Stock Up 0.2%

Shares of Axogen, Inc. traded near $44.95 on Wednesday. The company, with a market cap of $2.39 billion, has a forward P/E ratio of 61.72 and a beta of 1.118, indicating moderate market volatility. The stock's 52-week range has been between $9.35 and $45.83, with a 50-day moving average of $40.43 and a 200-day moving average of $30.40. Axogen maintains a strong financial position with a current ratio of 7.101 and a quick ratio of 4.994, alongside a low debt-to-equity ratio of 8.432.

Recent Earnings

For its recent earnings period, Axogen reported revenue of $238.1 million, reflecting a growth rate of 26.6%. Despite this growth, the company posted a net margin of -13.21% and a return on equity of -17.96%, indicating ongoing challenges in achieving profitability. Axogen is scheduled to announce its next earnings results on August 4, 2026.

Insider Buying and Selling at Axogen, Inc.

In addition to Burke William's acquisition, several other insiders made purchases on the same day. Wendell Amy McBride, Alan Levine, Kathy Johnson Weiler, and Joseph Tyndall each acquired 14,150 shares, while Paul Thomas purchased 18,867 shares. These transactions were not part of a pre-arranged trading plan, suggesting a collective insider confidence in Axogen's future prospects.

Analysts Set New Price Targets

Analysts remain optimistic about Axogen's potential. On April 29, 2026, Canaccord Genuity and Citizens both maintained their 'buy' ratings with a $50 price target. Wells Fargo also maintained a 'buy' rating with a $48 target. Overall, the consensus among nine analysts is a 'buy' rating, with a mean price target of $50.78.

About Axogen, Inc.

Axogen, Inc., based in Alachua, Florida, operates in the healthcare sector, focusing on medical devices for peripheral nerve regeneration and repair. It provides various products such as Avance Nerve Graft and Axoguard Nerve Connector, among others, to hospitals and surgery centers worldwide. Led by CEO Michael D. Dale, Axogen employs 622 people.

Bottom Line

Burke William's recent purchase of Axogen shares adds to a series of insider buys, indicating potential confidence in the company's trajectory. While Axogen continues to face profitability challenges, its revenue growth and institutional interest suggest a promising outlook. As always, it's important to remember that insider transactions are just one piece of the investment puzzle.